Blazing Trails with Actionable Genomics
Genomenon CEO Mike Klein elaborates on why it’s such an honor to receive the 2023 Frost & Sullivan Technology Innovation Best Practices Award.
Genomenon and Boston Genetics Join Forces to Curate the Human Genome
Founder Mark Kiel comments on today’s news of the acquisition of leading genomics interpretation and curation company, Boston Genetics, and what it means for the race to curate the human genome.
A Rare Breed: Focused on Rare Disease Therapeutics
For Rare Disease Day 2023, we celebrate 10 pharma and biotech companies that are working on cures and novel treatments for rare disease patients.
Diagnostic Perspectives from Lurie Children’s Hospital: The Value of Mastermind in Clinical CNV Interpretation
In a recent webinar, Dr. Kai Lee Yap, Director of Molecular Diagnostics at Lurie Children’s Hospital, speaks with the Genomenon team about how Mastermind is streamlining the variant interpretation process within the Department of Pathology and Laboratory Medicine.
Mastermind: The Engine Behind the Future of Newborn Sequencing
Last month’s World Orphan Drug Congress brought together more than 250 insightful speakers, including a key leader from Rady Children’s Hospital who focused on the new new BeginNGS™ (pronounced “beginnings”) program, based at the Rady Children’s Institute for Genomic Medicine (RCIGM).
OUR RARE STORIES | Rare Disease Day 2022
In honor of Rare Disease Day February 28, 2022, we are excited to present Genomenon’s “Our Rare Stories” Live Blog, where we will be compiling articles, informative webinars, press releases, and other compelling resources that all play a part in highlighting the inspiration for our mission—patient stories.